Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary ...
Australia’s access to affordable medicines could be under threat from global tensions, with one woman forced to fork out $220 ...
European commercialization introduces an additional aflibercept biosimilar option for major retinal indications, potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results